Heier Jeffrey S

Heier Jeffrey S, Ho Allen C, Samuel Michael A, Chang Tom, Riemann Christopher D, Kitchens John W et al.

A study on subretinal palucorcel for geographic atrophy found its novel delivery system was safe and effective. However, palucorcel showed no benefit in visual acuity or GA lesion growth, indicating no clinical efficacy.

Lee Gregory D, Goldberg Roger A, Heier Jeffrey S

Endoscopic vitrectomy for hypotony from anterior PVR after retinal detachment repair improved IOP in a minority, especially younger patients with fewer prior surgeries, but failed in most.

Chew Emily Y, Clemons Traci E, Bressler Susan B, Elman Michael J, Danis Ronald P, Domalpally Amitha et al.

A home monitoring device for age-related macular degeneration detected CNV earlier, resulting in significantly better visual acuity at diagnosis compared to standard care, improving treatment outcomes.

Campochiaro Peter A, Channa Roomasa, Berger Brian B, Heier Jeffrey S, Brown David M, Fiedler Ulrike et al.

MP0112, a novel anti-VEGF drug, showed prolonged vision and edema improvement in DME patients, but initial formulations caused inflammation. Impurities were identified and removed for future trials.

Brown David M, Heier Jeffrey S, Clark W Lloyd, Boyer David S, Vitti Robert, Berliner Alyson J et al.

Intravitreal aflibercept significantly improved vision in CRVO-related macular edema, with benefits maintained at one year with PRN dosing, offering an effective treatment option.

Shingleton Bradford J, Marvin Alicia C, Heier Jeffrey S, O'Donoghue Mark W, Laul Anupam, Wolff Brian et al.

This study found PXF eyes with preoperative zonular weakness signs or prior fellow-eye complications had significantly higher rates of vitrectomy during cataract surgery, yet achieved good visual and IOP outcomes.

Brown David M, Michels Mark, Kaiser Peter K, Heier Jeffrey S, Sy Judy P, Ianchulev Tsontcho

In neovascular AMD, ranibizumab significantly outperformed verteporfin PDT over two years, improving visual acuity and anatomical outcomes, establishing it as a superior treatment.

Heier Jeffrey S, Antoszyk Andrew N, Pavan Peter Reed, Leff Steven R, Rosenfeld Philip J, Ciulla Thomas A et al.

Ranibizumab injections for neovascular AMD safely improved vision and reduced leakage, demonstrating its efficacy for this sight-threatening condition.

Rosenfeld Philip J, Heier Jeffrey S, Hantsbarger Gary, Shams Naveed

Ranibizumab for neovascular AMD was studied; multiple escalating doses were well-tolerated and improved vision/lesion activity. This supports its clinical use in treating nAMD.